Inhibition of dopamine release by prostaglandin EP3 receptor via pertussis toxin-sensitive and -insensitive pathways in PC12 cells.
Prostaglandin EP3 receptor is involved in the inhibition of neurotransmitter release from presynaptic nerve terminals in various tissues. We have examined the regulation of neurotransmitter release by the EP3 receptor using a PC12 cell line that stably expresses the EP3B receptor isolated from bovine adrenal medulla. In the cells, M&B28767, an EP3 agonist, inhibited the 50 mM KCl- or 10 nM bradykinin-induced [3H]dopamine release in a concentration-dependent manner (10 pM to 0.1 microM). This inhibition was partially reversed by pretreatment with pertussis toxin, whereas under the same condition, the agonist-induced inhibition of forskolin-stimulated cyclic AMP accumulation was suppressed completely. In contrast, M&B28767 did not affect the high K(+)- or bradykinin-induced increase in intracellular Ca2+ concentration. Moreover, M&B28767 also inhibited the [3H]dopamine release induced by the Ca2+ ionophore ionomycin, and this inhibition was also partially reversed by pretreatment with pertussis toxin. These results indicate that the EP3 receptor is coupled to dual pathways, pertussis toxin-sensitive and -insensitive G-protein pathways, to regulate neurotransmitter release without changing Ca2+ influx in neuronal cells.
Department of Physiological Chemistry, Faculty of Pharmaceutical Sciences, Kyoto University, Japan.
K
K
Nakamura
H
H
Katoh
A
A
Ichikawa
M
M
Negishi
D000067956:Adenylyl Cyclase Inhibitors; D000527:Alprostadil / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology; D001426:Bacterial Proteins; D001920:Bradykinin / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism / Q000494:pharmacology; D015232:Dinoprostone / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D004789:Enzyme Activation / Q000187:drug effects; D019204:GTP-Binding Proteins / Q000378:metabolism*; D015759:Ionomycin / Q000494:pharmacology; D007476:Ionophores / Q000494:pharmacology; D018377:Neurotransmitter Agents / Q000378:metabolism; D016716:PC12 Cells; D037342:Pertussis Toxin; D011188:Potassium / Q000494:pharmacology; D051381:Rats; D018078:Receptors, Prostaglandin E / Q000378:metabolism*; D058308:Receptors, Prostaglandin E, EP3 Subtype; D013301:Streptolysins; D014316:Tritium; D010566:Virulence Factors, Bordetella / Q000494:pharmacology*
D000067956:Adenylyl Cyclase Inhibitors; D000897:Anti-Ulcer Agents; D001426:Bacterial Proteins; D007476:Ionophores; D018377:Neurotransmitter Agents; D018078:Receptors, Prostaglandin E; D058308:Receptors, Prostaglandin E, EP3 Subtype; D013301:Streptolysins; D010566:Virulence Factors, Bordetella; C025964:streptolysin O; D014316:Tritium; D015759:Ionomycin; C032405:11-deoxy-16-phenoxy-17,18,19,20-tetranorprostaglandin E1; D037342:Pertussis Toxin; D019204:GTP-Binding Proteins; D000527:Alprostadil; D015232:Dinoprostone; D011188:Potassium; D001920:Bradykinin; D002118:Calcium; D004298:Dopamine